Ensuring a steady, uninterrupted supply of Technetium 99m for our customers and the patients they serve is our top priority. Mallinckrodt is continuously making investments to increase worldwide stability of Mo-99 by constantly evaluating all potential long-term global supply opportunities and solutions.
Mallinckrodt’s Mo-99 LEU Conversion Efforts:
Conversion from high enriched uranium or HEU to low enriched uranium or LEU for Mo-99 production:
Demand for reliable, large-scale U.S. manufacture of Mo-99 using low-enriched uranium (LEU) technology.
Mallinckrodt’s Continued Investment in Manufacturing:
Investments are being made to our U.S. manufacturing facilities and products to improve quality and reliability.
Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.
© 2017 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland.